Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1206

Sort by

Sort Order Select

Journal Articles

Emerging therapies for inv(16) AML

Sridevi Surapally, Daniel G. Tenen, John A. Pulikkan

Blood (2021) 137 (19): 2579–2584.

https://doi.org/10.1182/blood.2020009933

Published: 2021

Journal Articles

Cryptic insertion of KMT2A , a rare t(9;11) variant

Nada Assaf, Christine Terré

Blood (2021) 137 (13): 1843.

https://doi.org/10.1182/blood.2020010442

Published: 2021

Journal Articles

Impaired condensin complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL

Blood (2020) 136 (3): 313–327.

https://doi.org/10.1182/blood.2019002538

Published: 2020

Includes: Supplemental data

Journal Articles

A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies

Hamid Bolouri, PhD, Benjamin K. Johnson, PhD, Rhonda E. Ries, MA, Laura Pardo, Tiffany A. Hylkema, BS, Wanding Zhou, PhD, Jenny L. Smith, MSc, MD, Amanda R. Leonti, MS, Allison Kaeding, MD, Michael R. Loken, PhD, Jason E. Farrar, MD, Soheil Meshinchi, MD PhD, Timothy Junius Triche, Jr., PhD

Blood (2019) 134 (Supplement_1): 3768.

https://doi.org/10.1182/blood-2019-123487

Published: 2019

Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Blood (2019) 134 (Supplement_1): 3806.

https://doi.org/10.1182/blood-2019-129018

Published: 2019

Journal Articles

Differentiating between Hyperdiploidy and Pseudo-Hyperdiploidy in B-Lymphoblastic Leukemia Utilizing Low-Coverage Mate-Pair Sequencing

James B Smadbeck, Beth A Pitel, MA, Kathryn E. Pearce, Sarah H Johnson, MS, Nicole Hoppman, Rhett P. Ketterling, MD, Patricia Griepp, MD, Linda B Baughn, PhD, George Vasmatzis, PhD, Jess Peterson, MD

Blood (2019) 134 (Supplement_1): 5212.

https://doi.org/10.1182/blood-2019-122440

Published: 2019

Journal Articles

MPO as a Novel Susceptibility Gene in Myeloid Malignancies

Samuel Li, BA, Ruipeng Wei, Janet Wang, Undergraduate, Vera Adema, PhD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, Yasunobu Nagata, MD PhD, Cassandra M Kerr, MS, Babal K. Jha, PhD, Francesc Sole, PhD, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Thomas Laframboise, PhD

Blood (2019) 134 (Supplement_1): 5402.

https://doi.org/10.1182/blood-2019-122127

Published: 2019

Journal Articles

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Blood (2019) 134 (Supplement_1): 4161.

https://doi.org/10.1182/blood-2019-127923

Published: 2019

Journal Articles

Molecular Characterization of Leukemia Evolving from Paroxysmal Nocturnal Hemoglobinuria

Hassan Awada, MD, Shafia Rahman, MBBS, Cassandra M Kerr, MS, Jibran Durrani, Vera Adema, PhD, Ashwin Kishtagari, MBBS, Sunisa Kongkiatkamon, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2019) 134 (Supplement_1): 2499.

https://doi.org/10.1182/blood-2019-131918

Published: 2019

Journal Articles

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Anna Kaci, PhD, Emilie Adiceam, Melanie Dupont, Marine Garrido, Jeannig Berrou, Hanane Djamai, Andre Baruchel, Mike Burbridge, Claude Gardin, Herve Dombret, MD PhD, Thorsten Braun, MD

Blood (2019) 134 (Supplement_1): 2631.

https://doi.org/10.1182/blood-2019-125641

Published: 2019

Journal Articles

Prognostic Significance of IKZF1 , PAX5 , and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib

Yuya Sasaki, MD PhD, Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Rebecca Garris, MSc, Nitin Jain, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Michael E. Rytting, MD, Guillermo Garcia-Manero, MD, Latasha Little, BS, Curtis Gumbs, Li Zhao, PhD, P. Andrew Futreal, PhD, Feng Wang, PhD, Koichi Takahashi, MD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2753.

https://doi.org/10.1182/blood-2019-122017

Published: 2019

Journal Articles

Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS)

Blood (2019) 134 (Supplement_1): 2578.

https://doi.org/10.1182/blood-2019-125131

Published: 2019

Journal Articles

Combination of Dasatinib and Pediatric-Inspired Regimens in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Center Prospective Study

Zhang Guang ji, Sr., master, Jianxiang Wang, MD, Ying Wang, Hui Wei, MD, Yingchang Mi, MD

Blood (2019) 134 (Supplement_1): 2583.

https://doi.org/10.1182/blood-2019-126480

Published: 2019

Journal Articles

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, Anne Lehman, Grace Jeschke, PhD, John D. Crispino, PhD MBA, Thierry Besson, PhD, Sarah K. Tasian, MD, Martin Carroll, MD

Blood (2019) 134 (Supplement_1): 2742.

https://doi.org/10.1182/blood-2019-123475

Published: 2019

Journal Articles

This Is a Title in Title Case: Prediction of CML Evolution By Telomere Length Analysis at the Single-Chromosome Level

Jingyuan Lu, Yingxing Zhou, Xiaomei Yan, Quanyi Lu

Blood (2019) 134 (Supplement_1): 2937.

https://doi.org/10.1182/blood-2019-126895

Published: 2019

Journal Articles

The Fanconi Anemia-Associated Protein NIPA Is Essential for the Nuclear Abundance of FANCD2

Blood (2019) 134 (Supplement_1): 3741.

https://doi.org/10.1182/blood-2019-125973

Published: 2019

Journal Articles

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Josep-Maria Ribera, MD PhD, Olga García, Pilar Martinez, MD, Pau Montesinos Fernandez, MD PhD, Blanca Boluda, Jordi Esteve, Daniel Esteban, María José Moreno, MD, Natalia Alonso, José González-Campos, MD, Arancha Bermúdez, Susana Vives, MD, Mar Tormo, MD PhD, Jesús María Hernández-Rivas, MD PhD, Joaquin Martinez-Lopez, MD PhD, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 3874.

https://doi.org/10.1182/blood-2019-125558

Published: 2019

Journal Articles

Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Bachar Samra, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Marina Y Konopleva, MD PhD, Rita Khouri, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Cesar Nunez, MD, Tapan M. Kadia, MD, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 3819.

https://doi.org/10.1182/blood-2019-127499

Published: 2019

Journal Articles

Impact of Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect Based on Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Yu Akahoshi, MD, Aiko Igarashi, MD, Takahiro Fukuda, Naoyuki Uchida, MD PhD, Masatsugu Tanaka, MD, Yukiyasu Ozawa, MD PhD, Yoshinobu Kanda, MD PhD, Makoto Onizuka, MD PhD, Tatsuo Ichinohe, Junji Tanaka, MD PhD, Yoshiko Atsuta, MD PhD, Shinichi Kako, MD

Blood (2019) 134 (Supplement_1): 4522.

https://doi.org/10.1182/blood-2019-123983

Published: 2019

Journal Articles

Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study

Liu Hui, MD, Li Xuan, MD, Ren Lin, MD, Lan Deng, MD PhD, Fen Huang, MD, Zhiping Fan, MD, Danian Nie, MD, Xudong Li, Xinquan Liang, Dan Xu, Yu Zhang, Na Xu, MD, Jieyu Ye, MD PhD, Hua Jin, Dongjun Lin, MD, Liping MA, MD, Jing Sun, MD, Xiaojun Huang, MD, Qifa Liu, MD

Blood (2019) 134 (Supplement_1): 3303.

https://doi.org/10.1182/blood-2019-126901

Published: 2019

NARROW

Emerging therapies for inv(16) AML

Cryptic insertion of KMT2A , a rare t(9;11) variant

Impaired condensin complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL

A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Differentiating between Hyperdiploidy and Pseudo-Hyperdiploidy in B-Lymphoblastic Leukemia Utilizing Low-Coverage Mate-Pair Sequencing

MPO as a Novel Susceptibility Gene in Myeloid Malignancies

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Molecular Characterization of Leukemia Evolving from Paroxysmal Nocturnal Hemoglobinuria

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Prognostic Significance of IKZF1 , PAX5 , and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib

Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS)

Combination of Dasatinib and Pediatric-Inspired Regimens in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Center Prospective Study

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

This Is a Title in Title Case: Prediction of CML Evolution By Telomere Length Analysis at the Single-Chromosome Level

The Fanconi Anemia-Associated Protein NIPA Is Essential for the Nuclear Abundance of FANCD2

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Impact of Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect Based on Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Pre-Emptive Tyrosine Kinase-Inhibitor Intervention Based on BCR/ABL1 Monitoring in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Allo-HSCT: Two Independent Observational Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only